These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Phase I and II clinical trials for the mucopolysaccharidoses. Poswar F; Baldo G; Giugliani R Expert Opin Investig Drugs; 2017 Dec; 26(12):1331-1340. PubMed ID: 29065735 [TBL] [Abstract][Full Text] [Related]
9. Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art. de Castro MJ; Del Toro M; Giugliani R; Couce ML Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502108 [TBL] [Abstract][Full Text] [Related]
10. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII. Bielicki J; McIntyre C; Anson DS Mol Genet Metab; 2010 Dec; 101(4):370-82. PubMed ID: 20864369 [TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of mucopolysaccharidoses. Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109 [TBL] [Abstract][Full Text] [Related]
12. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer. Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695 [TBL] [Abstract][Full Text] [Related]
13. Treatment of brain disease in the mucopolysaccharidoses. Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844 [TBL] [Abstract][Full Text] [Related]
14. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Kotterman MA; Chalberg TW; Schaffer DV Annu Rev Biomed Eng; 2015; 17():63-89. PubMed ID: 26643018 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Fraldi A; Serafini M; Sorrentino NC; Gentner B; Aiuti A; Bernardo ME Ital J Pediatr; 2018 Nov; 44(Suppl 2):130. PubMed ID: 30442177 [TBL] [Abstract][Full Text] [Related]
16. Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. Aronovich EL; Bell JB; Belur LR; Gunther R; Koniar B; Erickson DC; Schachern PA; Matise I; McIvor RS; Whitley CB; Hackett PB J Gene Med; 2007 May; 9(5):403-15. PubMed ID: 17407189 [TBL] [Abstract][Full Text] [Related]
17. Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities. Zapolnik P; Pyrkosz A Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070997 [TBL] [Abstract][Full Text] [Related]
18. Primary T lymphocytes as targets for gene therapy. Hanazono Y; Brown KE; Dunbar CE J Hematother Stem Cell Res; 2000 Oct; 9(5):611-20. PubMed ID: 11091484 [TBL] [Abstract][Full Text] [Related]
19. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Sferra TJ; Qu G; McNeely D; Rennard R; Clark KR; Lo WD; Johnson PR Hum Gene Ther; 2000 Mar; 11(4):507-19. PubMed ID: 10724030 [TBL] [Abstract][Full Text] [Related]
20. Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy. Chatterjee S; Lu D; Podsakoff G; Wong KK Ann N Y Acad Sci; 1995 Dec; 770():79-90. PubMed ID: 8597384 [No Abstract] [Full Text] [Related] [Next] [New Search]